^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    RPS6KB1 (Ribosomal Protein S6 Kinase B1)

    i
    Other names: RPS6KB1, Ribosomal Protein S6 Kinase B1, S6K1, Serine/Threonine-Protein Kinase 14A, Ribosomal Protein S6 Kinase Beta-1, Ribosomal Protein S6 Kinase I, P70(S6K)-Alpha, S6K-Beta-1, P70 S6KA, STK14A, PS6K, S6K, Ribosomal Protein S6 Kinase, 70kDa, Polypeptide 1, Ribosomal Protein S6 Kinase, 70kD, Polypeptide 1, 70 KDa Ribosomal Protein S6 Kinase 1, Serine/Threonine Kinase 14 Alpha, P70 Ribosomal S6 Kinase Alpha, P70 S6 Kinase, Alpha, P70 S6 Kinase Alpha, P70 S6K-Alpha, P70-Alpha, P70-S6K 1, P70-S6K, RPS6KB1, P70S6K1
    13d
    TP53 Loss Fuels mTORC1 Activation and Autophagy Suppression to Drive Immune-Cold Colorectal Cancer. (PubMed, World J Oncol)
    In MSS CRC, p53 deficiency is consistently associated with immunometabolic remodeling marked by persistent mTOR pathway activation, relative autophagy attenuation, and FOXP3-dominant immune-cold features across transcriptomic, single-cell, and proteomic layers. These findings add protein- and phosphosite-level evidence linking TP53 loss to an immune-suppressive metabolic state and support biomarker-guided evaluation of mTOR kinase (TORC1/2) inhibition, which more fully suppresses 4E-BP/S6K phosphorylation, combined with PD-1/PD-L1 (± CTLA-4) blockade in TP53-deficient MSS CRC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    TP53 (Tumor protein P53) • CD8 (cluster of differentiation 8) • RPS6KB1 (Ribosomal Protein S6 Kinase B1) • FOXP3 (Forkhead Box P3)
    |
    TP53 mutation • TP53 wild-type
    14d
    BACE2 facilitates lung adenocarcinoma progression by enhancing mTORC1 signalling. (PubMed, Transl Cancer Res)
    In vivo, BACE2 knockdown significantly suppressed xenograft tumor growth. BACE2 contributes to LUAD progression by activating the mTORC1 signalling pathway, providing a novel therapeutic target for LUAD treatment.
    Journal
    |
    RPS6KB1 (Ribosomal Protein S6 Kinase B1)
    24d
    Recent advances in the molecular genetic mechanisms and immune microenvironment of uveal melanoma. (PubMed, Melanoma Res)
    Clinically, the bispecific T-cell redirection drug Tebentafusp has achieved a major breakthrough in metastatic uveal melanoma immunotherapy. This review systematically elucidates key driver gene mutations, chromosomal abnormalities, epigenetic alterations, and the unique immunosuppressive microenvironment of uveal melanoma, providing new insights into mechanisms of treatment resistance and guiding the development of innovative therapeutic strategies.
    Journal • IO biomarker
    |
    GNAQ (G Protein Subunit Alpha Q) • BAP1 (BRCA1 Associated Protein 1) • RPS6KB1 (Ribosomal Protein S6 Kinase B1) • MIR181A1 (MicroRNA 181a-1)
    |
    Kimmtrak (tebentafusp-tebn)
    1m
    Proteomics and phosphoproteomics of human colorectal cancer cells lacking a specific kinase activity reveal kinase-specific compensatory responses. (PubMed, Anim Cells Syst (Seoul))
    Collectively, these findings elucidate how targeted kinase loss drives homeostatic signaling networks in cancer cells. By systemically characterizing cellular-level signaling changes and contextualizing them within known kinase pathways, our results provide insights into synthetic lethality and identify potential therapeutic targets to counteract adaptive resistance to kinase inhibitors.
    Journal
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PLK1 (Polo Like Kinase 1) • RPS6KB1 (Ribosomal Protein S6 Kinase B1)
    2ms
    Hsa_circ_0003176: a key player in the m6A modification-mediated regulation of autophagy and glycolysis in cisplatin-resistant non-small cell lung cancer. (PubMed, Hum Cell)
    In addition, in vivo xenograft models confirmed that hsa_circ_0003176 overexpression suppressed tumor growth and enhanced DDP sensitivity. Our study reveals the METTL3/m6A/hsa_circ_0003176/RPS6KB1 pathway as a critical pathway in NSCLC chemoresistance, offering novel therapeutic targets for overcoming DDP resistance.
    Journal
    |
    RPS6KB1 (Ribosomal Protein S6 Kinase B1) • RPS6 (Ribosomal Protein S6) • METTL3 (Methyltransferase Like 3)
    |
    cisplatin
    3ms
    Targeting PAK1 suppresses tumor progression by promoting mRNA decay of oncogenic factors and enhancing chemotherapeutic efficacy in colorectal cancer. (PubMed, Genes Dis)
    Importantly, our results revealed that the PAK1 inhibitor, PF3758309, exhibited a profound synergistic effect with oxaliplatin in CRC. Collectively, our study unveils a novel function of PAK1 in CRC progression. Thus, these results highlight the potential of targeting PAK1 as a therapeutic strategy in CRC, particularly in combination with oxaliplatin.
    Journal
    |
    CD44 (CD44 Molecule) • SAA1 (Serum Amyloid A1) • RPS6KB1 (Ribosomal Protein S6 Kinase B1) • PAK1 (p21 (RAC1) activated kinase 1) • EIF4G1 (Eukaryotic translation initiation factor 4 gamma, 1)
    |
    oxaliplatin • PF-3758309
    3ms
    Effects of miR-128-3p on Renal Inflammation in a Rat Periodontitis Model. (PubMed, Dent J (Basel))
    The potential target genes of activin A receptor type I (Acvr1), ribosomal protein S6 kinase B1 (Rps6kb1), and transforming growth factor beta receptor type 1 (Tgfbr1) were significantly lower in the kidneys of the LPS group. EVs-derived miR-128-3p in LPS induced periodontitis may cause kidney inflammation which may be mediated by, Rps6kb1, Tgfbr1, and Acvr1.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • ACVR1 (Activin A Receptor Type 1) • RPS6KB1 (Ribosomal Protein S6 Kinase B1) • RPS6 (Ribosomal Protein S6) • CX3CL1 (C-X3-C Motif Chemokine Ligand 1) • MIR128 (MicroRNA 128) • TGFBR1 (Transforming Growth Factor Beta Receptor 1)
    3ms
    BCAA (Branched-Chain Amino Acids) Inhibiting the Autophagy System via the Activation of mTORC1, Thereby Upregulating the Tumor Suppressor PDCD4 in Huh7 Hepatoma Cells. (PubMed, Cells)
    Additionally, BCAA upregulated the phosphorylation of ULK1 at serine 757, which was inhibited by rapamycin...Furthermore, FACS analysis showed that BCAA inhibited the proliferation of Huh7 cells. BCAA may have a preventive effect against tumor development through the modulation of autophagy and the tumor suppressor pathways.
    Journal
    |
    EGF (Epidermal growth factor) • EIF4EBP1 (Eukaryotic translation initiation factor 4E binding protein 1) • RPS6KB1 (Ribosomal Protein S6 Kinase B1)
    |
    sirolimus
    6ms
    Discovery of actionable drug targets to enhance T-cell infiltration and immune checkpoint blockade efficacy in pleural mesothelioma. (PubMed, Lung Cancer)
    This comprehensive transcriptomic characterization of T-cell exclusion in PM reveals that targeting cilium-based Hedgehog signaling, in addition to multiple other actionable drug targets, could enhance the efficacy of ICB treatment in PM.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • SMO (Smoothened Frizzled Class Receptor) • ACVR1 (Activin A Receptor Type 1) • RPS6KB1 (Ribosomal Protein S6 Kinase B1) • CMTM4 (CKLF Like MARVEL Transmembrane Domain Containing 4) • KDM5B (Lysine Demethylase 5B) • SOX4 (SRY-Box Transcription Factor 4) • BMPR1B (Bone Morphogenetic Protein Receptor Type 1B)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    7ms
    An integrated environmental toxicity risk assessment framework combining deep learning and molecular simulation: A case study on pyrethrins and breast cancer. (PubMed, Biochem Biophys Rep)
    This integrative methodology supports environmental exposure monitoring and toxicological policy development. The open-source, containerized analytical toolchain developed herein is highly extensible and adaptable for future toxicological evaluations of other natural compounds and emerging environmental pollutants.
    Journal
    |
    ER (Estrogen receptor) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • RPS6KB1 (Ribosomal Protein S6 Kinase B1)
    |
    ER positive
    8ms
    Gene fusion detection in long-read transcriptome sequencing data with GFvoter. (PubMed, BMC Genomics)
    Overall, our findings show that GFvoter can accurately identify gene fusions from long-read RNA-seq data, which has the potential to improve cancer diagnosis and treatment. GFvoter is available at https://github.com/xiaolan-z/GFvoter .
    Journal
    |
    RPS6KB1 (Ribosomal Protein S6 Kinase B1) • VMP1 (Vacuole Membrane Protein 1)
    8ms
    Novel kinase-activating genetic events in non-small cell lung carcinomas. (PubMed, Explor Target Antitumor Ther)
    ROS1, LTK, and FGFR4 high-level overexpression was observed in 1 out of 89 tumors each. This study demonstrates the scarcity of yet unknown kinase-activating alterations in NSCLCs.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • FGFR4 (Fibroblast growth factor receptor 4) • LTK (Leukocyte Receptor Tyrosine Kinase) • RPS6KB1 (Ribosomal Protein S6 Kinase B1) • CLIP1 (CAP-Gly Domain Containing Linker Protein 1) • KAT6B (Lysine Acetyltransferase 6B) • VMP1 (Vacuole Membrane Protein 1)